Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLCN061
- Development stage
- Preclinical
- Lead developer
- Akatsuki Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
**HLCN061** is an allogeneic gene-engineered human induced pluripotent stem cell derived natural killer cell therapy being developed by Healios in collaboration with Akatsuki Therapeutics for solid tumors. The product is an off-the-shelf iPSC-derived NK cell therapy designed to improve antitumor activity, persistence, tumor homing, and recruitment of host immune cells. Reported engineered features include expression of interleukin 15, C C motif chemokine receptor 2B, C C motif chemokine ligand 19, high-affinity CD16a, and natural killer group 2D with DAP10 support, with preclinical data showing enhanced cytotoxicity and antibody-dependent cellular cytotoxicity against multiple solid tumor models including hepatocellular carcinoma, lung cancer, malignant pleural mesothelioma, and metastatic uveal melanoma. As of 2026, it appears to remain in preclinical or early translational development with first-in-human testing planned but not yet confirmed as initiated.
- Other names
- eNK
Beyond the preview
Go deeper on HLCN061.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLCN061.